Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity.

PloS one - 1 Jan 2012

Billeskov Rolf, Elvang Tara T, Andersen Peter L, Dietrich Jes

Abstract excerpt

BACKGROUND: The current vaccine against tuberculosis (TB), BCG, has failed to control TB worldwide and the protective efficacy is moreover limited to 10-15 years. A vaccine that could efficiently boost a BCG-induced immune response and thus prolong protective immunity would therefore have a significant impact on the global TB-burden. METHODS/FINDINGS: In the present study we show that the fusion protein HyVac4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BCG Vaccine
Share to CD4-Positive T-Lymphocytes
Share to Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunization, Secondary

Share to Immunologic Memory

Share to Tuberculosis

Share to Vaccines, Subunit

Source

Open in PubMed Open full text

Identifiers

PMID: 22768165
DOI: 10.1371/journal.pone.0039909
PMCID: PMC3386939

Genes

MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity.PMID 22768165Read ↗

Mycobacterial EsxG·EsxH (TB9.8·TB10.4) peptides as a subunit vaccine to booster BCG vaccination in an experimental model of pulmonary TuberculosisSemantic proximity Read ↗

A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-GuérinSemantic proximity Read ↗

CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.Semantic proximity Read ↗

Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics.Semantic proximity Read ↗

MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB EpidemicSemantic proximity Read ↗

Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccineSemantic proximity Read ↗

A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and PrimatesSemantic proximity Read ↗

Recombinant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memorySemantic proximity Read ↗

Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potentialSemantic proximity Read ↗

New Advances in the Development and Design of Mycobacterium tuberculosis Vaccines: Construction and Validation of Multi-Epitope Vaccines for Tuberculosis PreventionSemantic proximity Read ↗

Improved Immune Responses and Tuberculosis Protection by Aerosol Vaccination with recombinant BCG expressing ESX-1 from <i>Mycobacterium marinum</i>Semantic proximity Read ↗

Developing next-generation tuberculosis vaccines based on pathogen–host interactions: Towards a holistic perspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.